DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements.

Inadequate attention has been paid to the frequent and often extensive cancer-associated DNA hypomethylation. This hypomethylation usually includes undermethylation of certain DNA repeats in constitutive heterochromatin, although it is not limited to such sequences. Many cancers display an overall deficiency in the levels of genomic 5-methylcytosine compared to a variety of normal postnatal somatic tissues. The immunodeficiency, centromeric region instability, facial anomalies (ICF) syndrome, a rare recessive DNA methyltransferase deficiency disease, results in a small decrease in the extent of global genomic methylation. In ICF, DNA hypomethylation is targeted to the satellite DNA in juxtacentromeric (centromere-adjacent) heterochromatin of chromosomes 1 and 16 (1qh and 16qh), which are prone to rearrangements in ICF lymphoid cells. Also, 1qh and 16qh DNA sequences frequently are hypomethylated in human cancers and rearrangements in their vicinity are overrepresented in cancers. These often lead to chromosome arm imbalances and gene dosage imbalances that could participate in carcinogenesis. Studies of ICF cells suggest that hypomethylation in the normally highly methylated 1qh and 16qh regions predisposes to heterochromatin decondensation in these regions, which in turn leads to elevated levels of rearrangements. Studies of ICF cells also suggest that some of these rearrangements, namely multiradial chromosomes with multiple arms joined in the pericentromeric region, may be unstable intermediates in formation of more stable pericentromeric rearrangements in cancer. Microarray gene expression analysis on ICF and normal lymphoblastoid cell lines suggests that this hypomethylation also may affect gene expression elsewhere in the genome.

[1]  David E. Misek,et al.  DNA methyltransferase 3B mutations linked to the ICF syndrome cause dysregulation of lymphogenesis genes. , 2001, Human molecular genetics.

[2]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[3]  S. Gasser,et al.  Positions of Potential:Nuclear Organization and Gene Expression , 2001, Cell.

[4]  M. Ehrlich,et al.  Hypersensitivity to radiation-induced non-apoptotic and apoptotic death in cell lines from patients with the ICF chromosome instability syndrome. , 2000, Mutation research.

[5]  M. Ehrlich,et al.  DNA hypomethylation and unusual chromosome instability in cell lines fromICF syndrome patients , 2000, Cytogenetic and Genome Research.

[6]  R. Kuick,et al.  Whole-genome methylation scan in ICF syndrome: hypomethylation of non-satellite DNA repeats D4Z4 and NBL2. , 2000, Human molecular genetics.

[7]  M. Ehrlich,et al.  Frequent hypomethylation in Wilms tumors of pericentromeric DNA in chromosomes 1 and 16. , 1999, Cancer genetics and cytogenetics.

[8]  M. Ehrlich,et al.  Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. , 1999, Mutation research.

[9]  S. Baylin,et al.  Hypomethylation of pericentromeric DNA in breast adenocarcinomas , 1998, International journal of cancer.

[10]  C. Wijmenga,et al.  Localization of the ICF syndrome to chromosome 20 by homozygosity mapping. , 1998, American journal of human genetics.

[11]  I. Pogribny,et al.  Hypomethylation of the rat glutathione S-transferase pi (GSTP) promoter region isolated from methyl-deficient livers and GSTP-positive liver neoplasms. , 1998, Carcinogenesis.

[12]  B. Barlogie,et al.  Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. , 1998, Blood.

[13]  M. Ehrlich,et al.  DNA demethylation and pericentromeric rearrangements of chromosome 1. , 1997, Mutation research.

[14]  D. Bourc’his,et al.  α-Satellite DNA methylation in normal individuals and in ICF patients: heterogeneous methylation of constitutive heterochromatin in adult and fetal tissues , 1997, Human Genetics.

[15]  J. Goodman,et al.  Comparison of effect of tumor promoter treatments on DNA methylation status and gene expression in B6C3F1 and C57BL/6 mouse liver and in B6C3F1 mouse liver tumors , 1997, Molecular carcinogenesis.

[16]  Mimi C. Yu,et al.  Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. , 1997, British Journal of Cancer.

[17]  M. Ehrlich,et al.  Preferential induction of chromosome 1 multibranched figures and whole-arm deletions in a human pro-B cell line treated with 5-azacytidine or 5-azadeoxycytidine. , 1997, Cytogenetics and cell genetics.

[18]  L. Poirier,et al.  Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. , 1995, Cancer research.

[19]  R. Weinberg,et al.  Suppression of intestinal neoplasia by DNA hypomethylation , 1995, Cell.

[20]  R. Jaenisch,et al.  Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  F. Ledeist,et al.  An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome. , 1993, Human molecular genetics.

[22]  J. Christman,et al.  Reversibility of changes in nucleic acid methylation and gene expression induced in rat liver by severe dietary methyl deficiency. , 1993, Carcinogenesis.

[23]  G. Thomas,et al.  Production of thyroid tumours in mice by demethylating agents. , 1992, Carcinogenesis.

[24]  L. Poirier,et al.  Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. , 1992, Cancer research.

[25]  A. Feinberg,et al.  Reduced genomic 5-methylcytosine content in human colonic neoplasia. , 1988, Cancer research.

[26]  J. Kandala,et al.  Liver cell turnover in rats fed a choline-devoid diet. , 1987, Carcinogenesis.

[27]  I. Weinstein,et al.  Oncogene-induced transformation of a rat embryo fibroblast cell line is enhanced by tumor promoters , 1986, Molecular and cellular biology.

[28]  E. Ormerod,et al.  Enhanced experimental metastatic capacity of a human tumor line following treatment with 5-azacytidine. , 1986, Cancer research.

[29]  N. Bouck,et al.  Induction of a step in carcinogenesis that is normally associated with mutagenesis by nonmutagenic concentrations of 5-azacytidine , 1984, Molecular and cellular biology.

[30]  R. Kerbel,et al.  Possible epigenetic mechanisms of tumor progression: Induction of high‐frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5‐azacytidine treatment , 1984, Journal of cellular physiology. Supplement.

[31]  M. Raffeld,et al.  Azacytidine-induced tumorigenesis of CHEF/18 cells: correlated DNA methylation and chromosome changes. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Ehrlich,et al.  The 5-methylcytosine content of DNA from human tumors. , 1983, Nucleic acids research.

[33]  M. Ehrlich,et al.  Tissue-specific differences in DNA methylation in various mammals. , 1983, Biochimica et biophysica acta.

[34]  A. Feinberg,et al.  Hypomethylation of ras oncogenes in primary human cancers. , 1983, Biochemical and biophysical research communications.

[35]  A. Feinberg,et al.  Hypomethylation distinguishes genes of some human cancers from their normal counterparts , 1983, Nature.

[36]  D. Case 5-azacytidine in refractory acute leukemia. , 1982, Oncology.

[37]  H. Nakhasi,et al.  Covalent modification and repressed transcription of a gene in hepatoma cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[38]  F F Becker,et al.  5-Methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result. , 1979, Biochemical and biophysical research communications.

[39]  W. J. Hadden,et al.  A Comparison of , 1971 .